Notably, the mRNA expression level of lysyl oxidase (Lox), which is considered a serum biomarker of liver fibrosis in patients with NAFLD,33 reverted in mice treated with EVs, along with the expression levels of Col1α1, Tgf-β1, Ltbp-1, and α-Sma. This evidence concerns the gene ACTA1 and metabolic dysfunction-associated steatotic liver disease.